The similar ixazomib concentrations and 20S proteasome inhibition in SW48 WT and G13D isogenic tumors suggests that KRAS pathway activation does not alter tumor exposure or target inhibition by ixazomib, but rather affects cellular response to proteasome inhibitor-induced stress. This evidence concerns the gene KRAS and neoplasm.